Sugi Predict

Sugi Predict / Compounds / SCHEMBL4915665

SCHEMBL4915665

SCHEMBL4915665

CC(C)Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCN(C)CC2)n1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 18/20 0.80
▸ MAPK13 O15264 2/20 0.57
▸ EGFR P00533 2/20 0.57
▸ CSNK1D P48730 2/20 0.57
▸ MAPK12 P53778 2/20 0.57
▸ MAPK11 Q15759 2/20 0.57
▸ CSNK1E P49674 1/20 0.57
▸ KCNH2 Q12809 1/20 0.57
▸ BRD4 O60885 2/20 0.56
▸ BRDT Q58F21 2/20 0.56
▸ BRD2 P25440 1/20 0.56
▸ BRD3 Q15059 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ MAP4K4 O95819 1/20 0.54
▸ RAF1 P04049 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27441160 0.89 MAPK14 (1.00) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL4585618 0.86 MAPK14 (1.00) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL4585949 0.85 MAPK14 (0.78) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL4593760 0.85 MAPK14 (0.78) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL6957344 0.85 MAPK14 (1.00) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL24170159 0.85 MAPK14 (0.66) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL28600437 0.85 MAPK14 (0.66) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL31447690 0.85 MAPK14 (0.66) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL24170158 0.85 MAPK14 (0.66) MAPK14MAPK13EGFRCSNK1DMAPK12
SCHEMBL31447746 0.85 MAPK14 (0.66) MAPK14MAPK13EGFRCSNK1DMAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1177299-A Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine SMITHKLINE BEECHAM CORP (US) 1998-03-25 — — CN claimed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase SCIOS INC. 2006-01-26 — — US disclosed
US-20050129729-A1 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. 2005-06-16 — — US disclosed
WO-2005032551-A1 TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE SCIOS INC. (US) 2005-04-14 — — WO disclosed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 — — US disclosed
US-20040162289-A1 Methods of promoting osteogenesis UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY 2004-08-19 — — US disclosed
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase SCIOS, INC. 2004-06-24 — — US disclosed
CN-1138546-C Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine ʷ��˿�������ȳ�ķ���޹�˾ 2004-02-18 — — CN disclosed
US-6150557-A REACTING COMPOUND CONTAINING SECONDARY AMIDE GROUPS WITH BENZENESULFINIC ACID OR ITS DERIVATIVE IN PRESENCE OF ACID CATALYST SMITHKLINE BEECHAM CORPORATION (US) 2000-11-21 — — US disclosed
CN-1177299-A Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine SMITHKLINE BEECHAM CORP (US) 1998-03-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase MAPKAPK5, MAPK1, MAPKAPK2 MAPK14 36/4885MAPK13 34/4885EGFR 2127/4885
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MAPK14 23/4885MAPK13 15/4885EGFR 2117/4885
US-20040162289-A1 Methods of promoting osteogenesis MAPK1, BMP2, MAPK3 MAPK14 23/4885MAPK13 15/4885EGFR 2117/4885
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885MAPK13 39/4885EGFR 4164/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885MAPK13 39/4885EGFR 4164/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 MAPK14 53/4885MAPK13 46/4885EGFR 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.